NeuroDerm Initiates Patient Enrollment in a Phase III Trial of ND0612L for the Treatment of PD


(August 25, 2016) – NeuroDerm, a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, announced that it has initiated enrollment of Parkinson's disease patients in a Phase III efficacy trial (trial 007, named the "iNDiGO" trial) of ND0612L, the company’s low-dose continuous, subcutaneously delivered levodopa/carbidopa (LD/CD) liquid formulation. Read more…

Click for a printer friendly version

Back to top